Literature DB >> 24101029

Combined management of atrial fibrillation and heart failure: case studies.

Frederik H Verbrugge1, Wilfried Mullens.   

Abstract

Atrial fibrillation (AF) and heart failure (HF) are omnipresent cardiovascular disorders with a substantial impact on morbidity and mortality. As both share common risk factors, their pathophysiology is highly interrelated and a lot of patients present with both conditions. Surprisingly, despite their high prevalence, there is a paucity of evidence regarding the optimal combined management of AF and HF. The initial treatment for new-onset AF in the context of HF should focus on anticoagulation, rate control and prompt electrical cardioversion in case of hemodynamic instability. Subsequently, attention should focus upon the underlying pathophysiological substrate. This often requires multidisciplinary collaboration, not only between different subspecialties of cardiology, but also among medical and paramedical caregivers, especially when underlying HF is present. AF often contributes to worsening HF symptoms, but options to maintain sinus rhythm are less successful in patients with structural heart disease. Therefore, rhythm control strategies, whether medical or through catheter/surgical ablation, should target specific groups of patients with a high likelihood of perceived benefit. Indeed, morbidity and mortality are similar with rate versus rhythm control in the general population. Carefully performed cardiac imaging is vital to select these cases that might benefit most from rhythm control. A special group of HF patients are the one with cardiac devices, as they can be continuously monitored, even through remote care systems. The latter likely involves dedicated nurse practitioners and general physicians. Again, a collaborative environment with a disease management strategy is needed to ensure an optimally working device and maximized benefits for the patient.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24101029     DOI: 10.1007/s10741-013-9410-y

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  38 in total

Review 1.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

Authors:  William H Maisel; Lynne Warner Stevenson
Journal:  Am J Cardiol       Date:  2003-03-20       Impact factor: 2.778

2.  Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling.

Authors:  Frederik H Verbrugge; Matthias Dupont; Maximo Rivero-Ayerza; Philippe de Vusser; Hugo Van Herendael; Jan Vercammen; Linda Jacobs; David Verhaert; Pieter Vandervoort; W H Wilson Tang; Wilfried Mullens
Journal:  J Card Fail       Date:  2012-11       Impact factor: 5.712

3.  Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments.

Authors:  Ian G Stiell; Catherine M Clement; Robert J Brison; Brian H Rowe; Bjug Borgundvaag; Trevor Langhan; Eddy Lang; Kirk Magee; Rob Stenstrom; Jeffrey J Perry; David Birnie; George A Wells
Journal:  Ann Emerg Med       Date:  2010-09-22       Impact factor: 5.721

4.  The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation.

Authors:  Niv Ad; Linda Henry; Sharon Hunt
Journal:  Eur J Cardiothorac Surg       Date:  2010-12-18       Impact factor: 4.191

5.  Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy.

Authors:  Marcelle D Smit; Alexander H Maass; Hans L Hillege; Ans C P Wiesfeld; Dirk J Van Veldhuisen; Isabelle C Van Gelder
Journal:  Eur J Heart Fail       Date:  2011-02-17       Impact factor: 15.534

6.  Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy.

Authors:  S L D'Ascia; C D'Ascia; V Marino; A Lombardi; R Santulli; M Chiariello; G Santulli
Journal:  Int J Clin Pract       Date:  2011-11       Impact factor: 2.503

7.  Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of pre-implantation characteristics on long-term outcome.

Authors:  Rutger J van Bommel; Carel Jan Willem Borleffs; Claudia Ypenburg; Nina Ajmone Marsan; Victoria Delgado; Matteo Bertini; Ernst E van der Wall; Martin J Schalij; Jeroen J Bax
Journal:  Eur Heart J       Date:  2010-08-07       Impact factor: 29.983

8.  The cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades.

Authors:  Timo Weimar; Stefano Schena; Marci S Bailey; Hersh S Maniar; Richard B Schuessler; James L Cox; Ralph J Damiano
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-11-17

9.  Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians.

Authors:  Frederik H Verbrugge; Matthias Dupont; Philippe De Vusser; Maximo Rivero-Ayerza; Hugo Van Herendael; Jan Vercammen; Linda Jacobs; David Verhaert; Pieter Vandervoort; W H Wilson Tang; Wilfried Mullens
Journal:  Eur J Heart Fail       Date:  2012-09-20       Impact factor: 15.534

10.  Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program.

Authors:  Wilfried Mullens; Richard A Grimm; Tanya Verga; Thomas Dresing; Randall C Starling; Bruce L Wilkoff; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2009-03-03       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.